Wang, Haiyong <br/><br/>
Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling.  [electronic resource] 

 -  International journal of oncology  Mar 2016 
 - 1229-41 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1791-2423 
<br/><br/><label>Standard No.: </label>10.3892/ijo.2016.3326  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Animals<br/>Aorta--pathology<br/>Apoptosis<br/>Bufanolides--administration & dosage<br/>Cell Cycle<br/>Cell Movement<br/>Cell Proliferation<br/>Cell Survival<br/>Chick Embryo<br/>Cytokines--metabolism<br/>Drug Synergism<br/>Enzyme Inhibitors--administration & dosage<br/>Enzyme-Linked Immunosorbent Assay<br/>Human Umbilical Vein Endothelial Cells<br/>Humans<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Neovascularization, Pathologic<br/>Niacinamide--administration & dosage<br/>Phenylurea Compounds--administration & dosage<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Random Allocation<br/>Rats<br/>Signal Transduction<br/>Sorafenib<br/>Vascular Endothelial Growth Factor A--metabolism